---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-269358"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-06-12T20:05:16+00:00"
generated_at: "2026-06-12T20:09:08.787480+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Xilio rebalances board classes, shareholders approve stock plan amendment

## Summary
- Daniel Curran re-elected Class II director, then resigned and reappointed Class III to equalize board classes; no compensation change.
- Stockholders approved Amended and Restated 2021 Stock Incentive Plan, adding prefunded warrant shares to annual evergreen increase.
- All four Class II director nominees and ratification of Ernst & Young as auditor approved at June 10, 2026 annual meeting.

## SEC filing metadata
- accession: 0001193125-26-269358
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-06-12T20:05:16+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/0001193125-26-269358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/xlo-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-269358
- JSON: https://secwatch.observer/filing/0001193125-26-269358.json
- Plain text: https://secwatch.observer/filing/0001193125-26-269358.txt

## Key facts
- Shareholder Votes
  Xilio Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: On June 10, 2026, the Company held the 2026 Annual Meeting. The following is a summary of the matters voted on at that meeting and the results of the votes on such matters. 1. The Company’s stockholders elected Akintunde Bello, Ph.D., Daniel Curran, M.D., Robert Ross, M.D. and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Votes For Votes Withheld Broker Non-Votes Akintunde Bello, Ph.D. 3,652,015 130,437 1,279,671 Daniel Curran, M.D. 3,709,598 72,854 1,279,671 Robert Ross, M.D. 3,719,795 62,657 1,279,671 Yuan Xu, Ph.D. 3,716,549 65,903 1,279,671
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/0001193125-26-269358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.